Jain PharmaBiotech, Feb 2012, Pages: 281
This report deals with transdermal drug delivery - an approach used to deliver drugs through the skin for therapeutic use as an alternative to oral,intravascular, subcutaneous and transmucosal
UBM Canon, Aug 2011, Pages: 90
This special report focuses on the market leaders for transdermal medicine as well as the products in development anticipated to head this area in the years to come. This compilation’s prescription
Greystone Associates, Feb 2011
The advantages of transdermal drug delivery for improving patient compliance, particularly for the treatment of chronic conditions, are well known. But growth of transdermal delivery has been
Greystone Associates, Dec 2010
management as a quality-of-life issue for patients and their families. Responding to this trend, drug developers are increasingly turning to transdermal formulations of pain management drugs. Because it has
Greystone Associates, June 2011
skills that can increase the level of involuntary non-compliance with therapeutic protocols, transdermal delivery of drugs targeting CNS disorders is generally viewed as a method that can increase patient
Research Facts Ltd, Jan 2011, Pages: 142
The Top 50 Transdermal Drug Delivery Technology Companies Worldwide completely updates and significantly expands, (from 98 to 142 pages), The Top 40 Transdermal Drug Delivery Technology Companies
Greystone Associates, Aug 2011 Transdermal drug patches offer the advantages of ease of use, painlessness, disposability, control of drug delivery and avoidance of first-pass metabolism by the liver. Advances in synthetic
Greystone Associates, March 2009, Pages: 180
Transdermal Skin Patches: Markets and Opportunities is a comprehensive evaluation and analysis of the markets, products and participants in the growing skin patch segment of the health care sector
Research Facts Ltd, July 2009, Pages: 98
The US Food and Drug Administration (FDA) approved the first transdermal patch products in 1981. These delivery systems provided the controlled systemic absorption of scopolamine for the prevention
Frost & Sullivan, Aug 2006
This Frost & Sullivan research service entitled U.S. Transdermal Drug Delivery Market provides pipeline analysis, forecasts, and technology overviews. In this research, Frost & Sullivan's expert
Life Science Analytics, March 2011, Pages: 36
TransDermal Technologies, Inc. (TTI)-Detailed Product Pipeline provides up to date insight into company’s business description, product information, pipeline details including both summary
VDM Publishing House, May 2010, Pages: 168
and formulation variables the transdermal iontophoretic delivery of hydromorphone hydrochloride can be controlled, and the possibility of obtaining therapeutically effective hydromorphone concentrations
Life Science Analytics, March 2011, Pages: 141
TransDermal Technologies, Inc. (TTI)-Therapeutic Competitors Report Report includes a business summary, tabular representation of the number and percentage of products in each therapeutic indication
Informa Healthcare, Feb 2002, Pages: 592
comprehensive coverage of the development, preparation, and application of topical and transdermal therapeutic systems. Recognized international experts discuss the bioequivalence of dermatological
Informa Healthcare, July 1997, Pages: 376
Provides an up-to-date and critical examination of biophysical techniques used in the analysis of molecular mechanisms underlying transdermal drug delivery as well as a physical and chemical
Informa Healthcare, Oct 2002, Pages: 328
Presents authoritative state-of-the-art discussions of the key issues pertinent to transdermal drug delivery, examining those topics necessary to enable a critical evaluation of a drug candidate
Greystone Associates, Aug 2011 Transdermal drug patches offer the advantages of ease of use, painlessness, disposability, control of drug delivery and avoidance of first-pass metabolism by the liver. Advances in synthetic
Business Insights, Oct 2011, Pages: 92
, oral, and transdermal reformulation strategies are examined with key technologies profiled.
Features and benefits:
- Understand the commercial benefits of drug reformulation
- Understand the main
Greystone Associates, Nov 2011
effectiveness against breakthrough pain and has become a commonly prescribed pain medication for most forms of cancer. Controlled release formulations that include transdermal patches and transmucosal tablets
Greystone Associates, Jan 2012
to a new generation of sophisticated, application-specific injection, inhalation and transdermal drug products designed to satisfy caregiver and patient preferences while addressing managed care initiatives
